NDAINJECTIONINJECTABLEPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTIN F2 ALPHA (dinoprost tromethamine) is a prostaglandin F2α analog administered by injection. It is indicated for obstetric and gynecological applications, primarily for inducing abortion and controlling postpartum hemorrhage. The drug works by stimulating uterine contractions through prostaglandin receptor activation.
Pre-Launch
Pre-launch stage indicates early-phase commercial planning; teams will focus on launch readiness, market access strategy, and regulatory execution rather than mature portfolio management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PROSTIN F2 ALPHA during pre-launch offers opportunity to build a brand from inception, requiring strong commercial execution and market access strategy. Career trajectory depends on successful launch adoption and competing prostaglandin positioning in obstetrics.
Brand ManagerProduct Manager
Worked on PROSTIN F2 ALPHA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.